Fig. 4: ROS generation and photothermal conversion capacity of TPDA-TDTA-COF, TPDA-BT-COF, and TPDA-ViBT-COF. | Nature Communications

Fig. 4: ROS generation and photothermal conversion capacity of TPDA-TDTA-COF, TPDA-BT-COF, and TPDA-ViBT-COF.

From: Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy

Fig. 4

a Illustration of the AIE COFs for efficient ROS generation and photothermal conversion. b ROS generation assessment of TPDA-BT-COF. c Comparison of the ROS production capacity of TPDA-TDTA-COF, TPDA-BT-COF, and TPDA-ViBT-COF. d Temperature change of TPDA-TDTA-COF, TPDA-BT-COF, and TPDA-ViBT-COF irradiated under a 660 nm laser irradiation with power density of 1.0 W cm−2. e Temperature change of TPDA-ViBT-COF with different concentrations. f In vivo thermal images of mice with or without TPDA-ViBT-COF treatment. g TEM images and particle size distribution of TPDA-ViBT-COF. Data were repeated thrice independently with similar results. Cytotoxicity of TPDA-TDTA-COF, TPDA-BT-COF, and TPDA-ViBT-COF without (h) or upon 660 nm laser irradiation (i), n = 3 independent samples, data are presented as mean ± SEM. PDT photodynamic therapy, PTT photothermal therapy, DCFH 2,7-Dichlorodihydrofluorescein diacetate, ROS reactive oxygen species. Source data are provided as a Source Data file.

Back to article page